These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 36460545)

  • 1. Molecular Targeted Therapy in Oncology Focusing on DNA Repair Mechanisms.
    Garzón-Hernández C; Ramírez-Merino N; Soberon MCM
    Arch Med Res; 2022 Dec; 53(8):807-817. PubMed ID: 36460545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
    Padella A; Ghelli Luserna Di Rorà A; Marconi G; Ghetti M; Martinelli G; Simonetti G
    J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
    Rabenau K; Hofstatter E
    Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment.
    Genta S; Martorana F; Stathis A; Colombo I
    Crit Rev Oncol Hematol; 2021 Dec; 168():103539. PubMed ID: 34800653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting DNA damage response pathways in cancer.
    Groelly FJ; Fawkes M; Dagg RA; Blackford AN; Tarsounas M
    Nat Rev Cancer; 2023 Feb; 23(2):78-94. PubMed ID: 36471053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations.
    Ngoi NYL; Westin SN; Yap TA
    Curr Opin Oncol; 2022 Sep; 34(5):559-569. PubMed ID: 35787597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Checkpoint Inhibitors in Tumors Harboring Homologous Recombination Deficiency: Challenges in Attaining Efficacy.
    Silva SB; Wanderley CWS; Colli LM
    Front Immunol; 2022; 13():826577. PubMed ID: 35211121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
    Lau CH; Seow KM; Chen KH
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
    Przybycinski J; Nalewajska M; Marchelek-Mysliwiec M; Dziedziejko V; Pawlik A
    Expert Opin Ther Targets; 2019 Sep; 23(9):773-785. PubMed ID: 31394942
    [No Abstract]   [Full Text] [Related]  

  • 11. DNA Repair Proteins as Therapeutic Targets in Ovarian Cancer.
    López-Camarillo C; Rincón DG; Ruiz-García E; Astudillo-de la Vega H; Marchat LA
    Curr Protein Pept Sci; 2019; 20(4):316-323. PubMed ID: 30215333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.
    Brown JS; O'Carrigan B; Jackson SP; Yap TA
    Cancer Discov; 2017 Jan; 7(1):20-37. PubMed ID: 28003236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting PARP1 to Enhance Anticancer Checkpoint Immunotherapy Response: Rationale and Clinical Implications.
    Wanderley CWS; Correa TS; Scaranti M; Cunha FQ; Barroso-Sousa R
    Front Immunol; 2022; 13():816642. PubMed ID: 35572596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
    Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
    Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy.
    Gou R; Dong H; Lin B
    Life Sci; 2020 Nov; 261():118434. PubMed ID: 32941897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP inhibitor resistance: the underlying mechanisms and clinical implications.
    Li H; Liu ZY; Wu N; Chen YC; Cheng Q; Wang J
    Mol Cancer; 2020 Jun; 19(1):107. PubMed ID: 32563252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive biomarkers for cancer therapy with PARP inhibitors.
    Michels J; Vitale I; Saparbaev M; Castedo M; Kroemer G
    Oncogene; 2014 Jul; 33(30):3894-907. PubMed ID: 24037533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New perspective on DNA response pathway (DDR) in glioblastoma, focus on classic biomarkers and emerging roles of ncRNAs.
    Pirlog BO; Ilut S; Pirlog R; Chiroi P; Nutu A; Radutiu DI; Cuc GD; Berindan-Neagoe I; Nabavi SF; Filosa R; Nabavi SM
    Expert Rev Mol Med; 2023 May; 25():e18. PubMed ID: 37154101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The DNA Damaging Revolution: PARP Inhibitors and Beyond.
    Yap TA; Plummer R; Azad NS; Helleday T
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():185-195. PubMed ID: 31099635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy.
    Aktas BY; Guner G; Guven DC; Arslan C; Dizdar O
    Expert Rev Anticancer Ther; 2019 Jul; 19(7):589-601. PubMed ID: 31181965
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.